Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Stopped terminated due to lack of enrollment

Conditions

• Endocarditis, Bacterial
• Infective Endocarditis

Interventions

• DRUG: daptomycin
• DRUG: vancomycin

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)